Functional mapping of androgen receptor enhancer activity.
Cell Line, Tumor
Enhancer Elements, Genetic
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Genome, Human
Humans
Male
Molecular Sequence Annotation
Mutation
/ genetics
Polymorphism, Single Nucleotide
/ genetics
Prostatic Neoplasms
/ genetics
Receptors, Androgen
/ genetics
Reproducibility of Results
Androgen receptor
Enhancers
Non-coding mutations
Prostate cancer
STARRseq
Journal
Genome biology
ISSN: 1474-760X
Titre abrégé: Genome Biol
Pays: England
ID NLM: 100960660
Informations de publication
Date de publication:
11 05 2021
11 05 2021
Historique:
received:
22
08
2020
accepted:
02
04
2021
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Androgen receptor (AR) is critical to the initiation, growth, and progression of prostate cancer. Once activated, the AR binds to cis-regulatory enhancer elements on DNA that drive gene expression. Yet, there are 10-100× more binding sites than differentially expressed genes. It is unclear how or if these excess binding sites impact gene transcription. To characterize the regulatory logic of AR-mediated transcription, we generated a locus-specific map of enhancer activity by functionally testing all common clinical AR binding sites with Self-Transcribing Active Regulatory Regions sequencing (STARRseq). Only 7% of AR binding sites displayed androgen-dependent enhancer activity. Instead, the vast majority of AR binding sites were either inactive or constitutively active enhancers. These annotations strongly correlated with enhancer-associated features of both in vitro cell lines and clinical prostate cancer samples. Evaluating the effect of each enhancer class on transcription, we found that AR-regulated enhancers frequently interact with promoters and form central chromosomal loops that are required for transcription. Somatic mutations of these critical AR-regulated enhancers often impact enhancer activity. Using a functional map of AR enhancer activity, we demonstrated that AR-regulated enhancers act as a regulatory hub that increases interactions with other AR binding sites and gene promoters.
Sections du résumé
BACKGROUND
Androgen receptor (AR) is critical to the initiation, growth, and progression of prostate cancer. Once activated, the AR binds to cis-regulatory enhancer elements on DNA that drive gene expression. Yet, there are 10-100× more binding sites than differentially expressed genes. It is unclear how or if these excess binding sites impact gene transcription.
RESULTS
To characterize the regulatory logic of AR-mediated transcription, we generated a locus-specific map of enhancer activity by functionally testing all common clinical AR binding sites with Self-Transcribing Active Regulatory Regions sequencing (STARRseq). Only 7% of AR binding sites displayed androgen-dependent enhancer activity. Instead, the vast majority of AR binding sites were either inactive or constitutively active enhancers. These annotations strongly correlated with enhancer-associated features of both in vitro cell lines and clinical prostate cancer samples. Evaluating the effect of each enhancer class on transcription, we found that AR-regulated enhancers frequently interact with promoters and form central chromosomal loops that are required for transcription. Somatic mutations of these critical AR-regulated enhancers often impact enhancer activity.
CONCLUSIONS
Using a functional map of AR enhancer activity, we demonstrated that AR-regulated enhancers act as a regulatory hub that increases interactions with other AR binding sites and gene promoters.
Identifiants
pubmed: 33975627
doi: 10.1186/s13059-021-02339-6
pii: 10.1186/s13059-021-02339-6
pmc: PMC8112059
doi:
Substances chimiques
Receptors, Androgen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Références
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):707-714
pubmed: 30602500
Genome Biol. 2014;15(12):550
pubmed: 25516281
Prostate. 2004 Jun 1;59(4):426-35
pubmed: 15065091
Nucleic Acids Res. 2017 Jan 25;45(2):619-630
pubmed: 27672034
Nat Struct Mol Biol. 2019 Mar;26(3):193-203
pubmed: 30833784
Nat Biotechnol. 2016 Nov;34(11):1180-1190
pubmed: 27701403
EMBO J. 2019 Sep 16;38(18):e101426
pubmed: 31373033
Mol Cell. 2018 Sep 6;71(5):858-871.e8
pubmed: 30078726
Genome Res. 2019 Feb;29(2):223-235
pubmed: 30606742
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Cancer Res. 2015 May 15;75(10):1944-8
pubmed: 25808865
Nat Rev Urol. 2017 Jan;14(1):38-48
pubmed: 27872477
Nat Genet. 2021 Mar;53(3):403-411
pubmed: 33633365
Bioinformatics. 2010 Sep 1;26(17):2204-7
pubmed: 20639541
BMC Genomics. 2015 Nov 17;16:963
pubmed: 26576536
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Genome Biol. 2012 Oct 03;13(10):R88
pubmed: 23034120
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
Nucleic Acids Res. 2020 Jul 9;48(12):6597-6610
pubmed: 32479598
Endocr Rev. 2004 Apr;25(2):276-308
pubmed: 15082523
Nat Methods. 2018 Dec;15(12):992-993
pubmed: 30504875
PLoS One. 2019 Aug 13;14(8):e0220311
pubmed: 31408468
Nucleic Acids Res. 2015 Jan;43(2):848-61
pubmed: 25552417
Nature. 2017 Mar 23;543(7646):519-524
pubmed: 28273065
Cell. 1981 Dec;27(2 Pt 1):299-308
pubmed: 6277502
Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2191-9
pubmed: 24821768
EMBO Rep. 2018 Dec;19(12):
pubmed: 30413482
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
PLoS One. 2013 Dec 10;8(12):e77922
pubmed: 24339862
Nat Genet. 2015 Nov;47(11):1346-51
pubmed: 26457646
Nature. 2013 Nov 14;503(7475):290-4
pubmed: 24141950
Nature. 2015 Feb 19;518(7539):317-30
pubmed: 25693563
Nat Genet. 2016 Oct;48(10):1260-6
pubmed: 27571262
Oncogene. 2018 Jan 18;37(3):313-322
pubmed: 28925401
Stat Appl Genet Mol Biol. 2012 Mar 31;11(3):Article 9
pubmed: 22499706
Genome Res. 2017 Jan;27(1):38-52
pubmed: 27831498
Nat Genet. 2010 Apr;42(4):343-7
pubmed: 20208536
Cell Stem Cell. 2018 Aug 02;23(2):276-288.e8
pubmed: 30033119
Cell. 2013 Apr 11;153(2):307-19
pubmed: 23582322
PLoS Genet. 2014 Jan 30;10(1):e1004102
pubmed: 24497837
Nat Methods. 2018 Feb;15(2):141-149
pubmed: 29256496
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7319-24
pubmed: 24778216
Nat Methods. 2017 Oct;14(10):975-978
pubmed: 28825706
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Cell Rep. 2016 Jun 7;15(10):2159-2169
pubmed: 27239026
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Genetics. 1988 Nov;120(3):621-3
pubmed: 2852134
Cancer Cell. 2019 Dec 9;36(6):674-689.e6
pubmed: 31735626
Nat Genet. 2007 Mar;39(3):311-8
pubmed: 17277777
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Genome Biol. 2017 Nov 20;18(1):219
pubmed: 29151363
Curr Protoc Bioinformatics. 2014 Sep 08;47:11.12.1-34
pubmed: 25199790
Nature. 2020 Feb;578(7793):102-111
pubmed: 32025015
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Cancer Cell. 2010 May 18;17(5):443-54
pubmed: 20478527
Cell. 2016 Aug 25;166(5):1269-1281.e19
pubmed: 27565349
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Cell. 2018 Oct 18;175(3):889
pubmed: 30340047
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Science. 2013 Mar 1;339(6123):1074-7
pubmed: 23328393
Genome Biol. 2020 Feb 21;21(1):45
pubmed: 32085783
Cell. 2018 Jul 12;174(2):422-432.e13
pubmed: 29909987
Nat Commun. 2018 Nov 21;9(1):4900
pubmed: 30464211
Nat Struct Mol Biol. 2016 Apr;23(4):349-57
pubmed: 26926434
Cancer Cell. 2013 Jan 14;23(1):35-47
pubmed: 23260764
Cell. 2018 Jul 12;174(2):433-447.e19
pubmed: 29909985
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Life Sci Alliance. 2018 Dec 28;2(1):e201800115
pubmed: 30620009
Oncogene. 2014 Dec 11;33(50):5666-74
pubmed: 24292680
Nat Commun. 2020 Feb 11;11(1):832
pubmed: 32047165
Cell. 2008 Jan 25;132(2):311-22
pubmed: 18243105
PLoS One. 2015 Mar 25;10(3):e0121318
pubmed: 25807461